Quick Answer
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported Total Assets of $15.92 million for the year ending 2025.
- REVIVA PHARMACEUTICALS HOLDINGS, INC. showed an increase of +2.7% in Total Assets from 2024 to 2025.
- This data is from REVIVA PHARMACEUTICALS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: $65.05 million | Q4 2018: $65.34 million | Q2 2019: $65.99 million | Q3 2019: $66.27 million | Q4 2019: $66.47 million | Q1 2020: $61.02 million | Q2 2020: $34.46 million | Q3 2020: $34.48 million | Q4 2020: $34.69 million | Q1 2021: $6.66 million | Q2 2021: $36.53 million | Q3 2021: $33.89 million | Q1 2022: $25.27 million | Q2 2022: $20.64 million | Q3 2022: $24.04 million | Q1 2023: $12.90 million | Q2 2023: $11.84 million | Q3 2023: $5.39 million | Q1 2024: $13.50 million | Q2 2024: $8.05 million | Q3 2024: $7.63 million | Q1 2025: $7.08 million | Q2 2025: $11.63 million | Q3 2025: $14.33 million.
- Over the full 9 years of available data (2019 to 2025), REVIVA PHARMACEUTICALS HOLDINGS, INC.'s Total Assets has declined by 75.7%.
- Historical annual values: Fiscal year 2025: $15.92 million | Fiscal year 2024: $15.50 million | Fiscal year 2023: $23.70 million | Fiscal year 2022: $18.92 million | Fiscal year 2021: $31.40 million | Fiscal year 2020: $8.76 million | Fiscal year 2020: $61.02 million | Fiscal year 2019: $2.6 thousand | Fiscal year 2019: $65.65 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: